Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Companyâ€™s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.

Employees

3,580

Sector

Advanced Medical Equipment & Technology

More about the company

Quotes

Date	Price	Change	Volume
13/03/26	34.40 $	-2.00%	186,261
12/03/26	35.10 $	-6.35%	900,547
11/03/26	37.48 $	-3.87%	716,739
10/03/26	38.99 $	-2.11%	447,068
09/03/26	39.83 $	-3.56%	437,728

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

35.10USD

Average target price

57.43USD

Spread / Average Target

+63.61%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 16:47:30 13/03/2026 GMT			5-day change	1st Jan Change
34.07 ^USD	-2.93%		-16.71%	-24.07%

02-06	Omnicell, Inc., Q4 2025 Earnings Call, Feb 05, 2026
02-05	Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026	CI

Capitalization	1.59B 1.38B 1.25B 1.19B 2.17B 147B 2.25B 14.89B 5.91B 70.35B 5.98B 5.86B 254B	P/E ratio 2026 *	85.3x	P/E ratio 2027 *	45.5x
Enterprise value	1.59B 1.38B 1.25B 1.19B 2.17B 147B 2.25B 14.89B 5.91B 70.35B 5.98B 5.86B 254B	EV / Sales 2026 *	1.29x	EV / Sales 2027 *	1.22x
Free-Float	80.46%	Yield 2026 *	-	Yield 2027 *	-

02-06	Omnicell, Inc., Q4 2025 Earnings Call, Feb 05, 2026
02-05	Omnicell, Inc. Provides Earnings Guidance for the First Quarter and Full Year 2026	CI
02-05	Omnicell, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-05	Omnicell Q4 Non-GAAP Net Income Falls, Revenue Rises; 2026 Guidance Issued	MT
02-05	(OMCL) Omnicell, Inc. Expects Q1 Revenue Range $300.0M - $310.0M	MT
02-05	(OMCL) Omnicell, Inc. Expects Q1 Adjusted EPS Range $0.26 - $0.36	MT
02-05	Earnings Flash (OMCL) Omnicell, Inc. Reports Q4 Revenue $314.0M, vs. FactSet Est of $313.4M	MT
02-05	Earnings Flash (OMCL) Omnicell, Inc. Posts Q4 Adjusted EPS $0.40 per Share, vs. FactSet Est of $0.50	MT
02-04	BofA Upgrades Omnicell to Buy From Neutral	MT
01-29	Gartner, Inc. Announces Board Appointments, Effective from January 29, 2026	CI
01-08	Omnicell Shares Rise After KeyBanc Upgrade	MT
01-08	KeyBanc Upgrades Omnicell to Overweight From Sector Weight, $60 Price Target	MT
12-09	Omnicell, Inc. - Special Call

02-04	BofA Upgrades Omnicell to Buy From Neutral	MT
01-08	Omnicell Shares Rise After KeyBanc Upgrade	MT
01-08	KeyBanc Upgrades Omnicell to Overweight From Sector Weight, $60 Price Target	MT
23/05/25	Piper Sandler Adjusts Omnicell Price Target to $57 From $46, Maintains Overweight Rating	MT
14/05/25	Wells Fargo Upgrades Omnicell to Overweight From Equal Weight, Adjusts Price Target to $35 From $31	MT

Omnicell, Inc. Share Price

Equities

OMCL

US68213N1090

Advanced Medical Equipment & Technology

Valuation: Omnicell, Inc.

Chart: Omnicell, Inc.

Latest news: Omnicell, Inc.

Last Transcript: Omnicell, Inc.

Analysts' recommendations: Omnicell, Inc.

Press Releases: Omnicell, Inc.

News in other languages: Omnicell, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Omnicell, Inc.

ETFs: Omnicell, Inc.

Medical Software & Technology Services

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

02-05	Omnicell : Investor Presentation	PU
02-05	Omnicell: Q4 Earnings Snapshot	AQ
02-05	Omnicell Announces Fiscal Year and Fourth Quarter 2025 Financial Results	BU
01-13	Omnicell to Release Fourth Quarter and Full Year 2025 Financial Results on February 5, 2026	BU
12-08	Announcing Omnicell Titan XT, the Next Generation, Automated Dispensing System Designed to Empower Autonomous Medication Management	BU

15/07/22	USA-Les valeurs à suivre à Wall Street (actualisé)
05/01/21	Omnicell : kooperiert im Rahmen der Ausweitung der Omnicell-Systeme im gesamten South East London NHS Integrated Care System mit dem Guy's and St Thomas' NHS Foundation Trust, London, bei der Entwicklung eines europäischen, technologiegestützten...
05/01/21	Omnicell : s’associe au Guy’s and St Thomas’ NHS Foundation Trust de Londres pour le développement d’un centre européen de veille technologique, dans le cadre de l’expansion des systèmes d’Omnicell dans l’ensemble du South East London NHS Integrated...
04/01/21	Quels ETF choisir pour investir dans les valeurs moyennes ?
09/12/20	USA-Les valeurs à suivre à Wall Street (actualisé)

1 day	-2.93%
1 week	-16.71%
Current month	-16.31%
1 month	-5.76%
3 months	-20.50%
6 months	+6.63%
Current year	-24.07%

1 week	34.34	40.71
1 month	34.34	42.6
Current year	34.34	55
1 year	22.66	55
3 years	22.66	77.14
5 years	22.66	187.28
10 years	22.66	187.28

Manager	Title	Age	Since
Randall Lipps CEO	Chief Executive Officer	68	30/09/2002
Harlan Radford DFI	Director of Finance/CFO	56	14/09/2025
Perry Genova CTO	Chief Tech/Sci/R&D Officer	-	30/03/2025

Director	Title	Age	Since
Randall Lipps CHM	Chairman	68	31/08/1992
Mark Parrish BRD	Director/Board Member	70	31/12/2012
Joanne Bauer BRD	Director/Board Member	70	31/12/2013

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
OMNICELL, INC.	-2.93%	-16.71%	+6.56%	-34.05%	1.59B
VEEVA SYSTEMS INC.	-1.07%	-8.18%	-21.20%	+6.18%	29.72B
PRO MEDICUS LIMITED	-0.41%	+9.47%	-41.73%	+116.68%	9.9B
SECTRA AB	+1.84%	+9.43%	+4.86%	+64.35%	4.7B
QINGSONG HEALTH CORPORATION	+4.27%	+37.12%	-	-	3.27B
HEARTFLOW, INC.	-1.47%	-10.14%	-	-	1.77B
GENERATE BIOMEDICINES, INC.	-0.83%	+16.46%	-	-	1.69B
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-1.89%	-0.99%	-52.04%	-	1.18B
B-SOFT CO.,LTD.	-1.58%	-0.40%	-35.41%	-46.51%	1.14B
YIDU TECH INC.	-1.85%	+3.91%	-16.19%	-19.53%	781M
Average	-0.59%	+3.39%	-22.16%	+14.52%	5.57B
Weighted average by Cap.	-0.52%	+0.60%	-22.94%	+31.75%

	2026 *	2027 *
Net sales	1.24B 1.08B 973M 929M 1.69B 115B 1.75B 11.58B 4.6B 54.72B 4.65B 4.56B 198B	1.31B 1.14B 1.03B 980M 1.78B 121B 1.84B 12.21B 4.85B 57.72B 4.91B 4.81B 208B
Net income	18.63M 16.16M 14.61M 13.95M 25.37M 1.72B 26.26M 174M 69.04M 822M 69.9M 68.41M 2.97B	35.38M 30.69M 27.75M 26.5M 48.19M 3.27B 49.88M 330M 131M 1.56B 133M 130M 5.63B
Net Debt	-	-